Adding Decitabine & Venetoclax to RIC Pre-Allo SCT
A Phase I Trial to Evaluate the Safety and Efficacy of Addition of Novel Anti-leukemia Agents to Flu/Mel RIC Transplant for High-risk Myeloid Malignancies
More Information
- Trial Status
- Accepting patients
- Trial Phase
- Phase 1
- Enrollment
- 20 patients (estimated)
- Sponsors
- University of Alabama at Birmingham
- Tags
- Hypomethylating Agents (HMA), BCL-2 Inhibitor, High Risk, Pre-Allogeneic Stem Cell Transplant
- Trial Type
- Treatment
- Last Update
- SparkCures ID
- 2166
- NCT Identifier
- NCT07044544
Real People. Real Support.
Need help connecting with this clinical trial? We're here to help!
Print a patient-friendly report to share with your patient.
We can help answer any questions and connect you (or your patient) with the study team.
Schedule a time that is convenient and we’ll call you to see how we can help you and your patient.